drugset / Trial / NCT00740779

Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

NCT00740779

Phase 2 Completed 153 enrolled Watson Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo.

Timeline

Start
2008-09
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Silodosin Unknown 4 mg
Subject Silodosin Unknown 8 mg

Indications